Skip to content

Design Validation of Senofilcon A With New UV-blocking Additive

Design Validation of Senofilcon A With New UV-blocking Additive

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03707821
Enrollment
253
Registered
2018-10-16
Start date
2018-10-01
Completion date
2018-11-01
Last updated
2019-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Visual Acuity

Brief summary

This is a 2-visit, multi-site, partially subject-masked, 2-arm parallel, controlled, randomized and dispensing trial. Subjects will be randomized to one of two study lenses for the entire duration of the study. The study lenses will be worn for a period of 2 weeks each in a bilateral fashion.

Interventions

JJVC Investigational Contact Lens

Acuvue Oasys

Sponsors

Johnson & Johnson Vision Care, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 49 Years
Healthy volunteers
Yes

Inclusion criteria

* Potential subjects must satisfy all of the following criteria to be enrolled in the study: 1. The subject must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form. 2. Appear able and willing to adhere to the instructions set forth in this clinical protocol. 3. Between 18 and 49 (inclusive) years of age at the time of informed consent. 4. Eligible presbyopes will be those that wear full distance contact lenses in both eyes, then wear reading glasses over them when needed for near vision. 5. The subject is a current spherical soft contact lens wearer in both eyes with a minimum of 6 hours/day and 5 days/week wear time over the last 30 days by self-report. 6. Subjects must be able and willing to wear the study lenses at least 6 hours a day, a minimum of 5 days per week. 7. Subjects must own a wearable pair of distance spectacles. 8. The subject's vertex-corrected spherical equivalent distance refraction must be in the range of -1.00 to -6.00 D (inclusive) in each eye. 9. The subject's refractive cylinder must be 0.00 to -1.00 D (inclusive) in each eye. 10. The subject must have a spherocylindrical best corrected distance Snellen visual acuity of 20/25+3 or better in each eye.

Exclusion criteria

* Potential subjects who meet any of the following criteria will be excluded from participating in the study: 1. Currently pregnant or lactating (subjects who become pregnant during the study will be discontinued). 2. Any active or ongoing systemic disease (e.g., Sjögren's Syndrome), infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive diseases (e.g., HIV), autoimmune disease (e.g. rheumatoid arthritis). 3. Subjects taking suspect oral medications for less than one year. 4. Any prescribed or over the counter (OTC) ocular medication. 5. Any known hypersensitivity or allergic reaction to Optifree® PureMoist® multi-purpose care solution or Eye-Cept® rewetting drop solution. 6. Toric, extended wear, monovision or multi-focal contact lens correction. 7. Any previous or planned (during the course of the study) ocular surgery (e.g., PRK, LASIK, etc.). 8. Participation in any contact lens or lens care product clinical trial within 30 days prior to study enrollment. 9. Participation in clinical trials involving the Test lens within 3 months prior to study enrollment. 10. Employee or immediate family member of an employee of clinical site (e.g., Investigator, Coordinator, Technician). 11. Binocular vision abnormality or strabismus by self-report or prior medical history. 12. History of recurrent corneal erosions, herpetic keratitis, or pathological dry eye. 13. Any active ocular allergies, infections or other ocular abnormalities (entropion, ectropion, extrusions, chalazia, recurrent styes, glaucoma) that the investigator determines may interfere with the outcomes of this study or otherwise contraindicate participation in the study. 14. Any Grade 2 or greater slit lamp findings (e.g., edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) on the FDA Slit Lamp Classification Scale. 15. Any previous history or signs of a contact lens-related corneal inflammatory event (e.g., past peripheral ulcer or round peripheral scar) within the past 3 years of otherwise successful contact lens wear.

Design outcomes

Primary

MeasureTime frameDescription
Vision Satisfaction in Bright Lighting2-Week Follow-up EvaluationVision satisfaction in bright light was assessed using the individual item I was satisfied with the quality of my vision in bright lighting from the CLUE™ questionnaire. This item used the response scale, 1: Strongly Disagree, 2: Disagree, 3: Neither Agree nor Disagree, 4: Agree and 5: Strongly Agree. CLUE is the Contact Lens User Experience™ questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120. The Proportion of responses in each category were reported for each lens type.
Contact Lens Fitting Acceptance RateUp to 2-Week Follow-upAcceptable lens fit will be assessed at all study visits (scheduled and unscheduled) for each subject eye. Fit acceptance rate will be based on the lens fit acceptance of eyes wearing the Test lens only. Fit acceptance is a binary response where Y=1 if lens fit is acceptable and Y=0 otherwise. Unacceptable is defined as unacceptable if any one of the following criteria: * limbal exposure at primary gaze or with extreme eye movement; * edge lift; * excessive movement in primary up gaze; * insufficient movement in all three of the following conditions: primary gaze, up gaze, and push up test. Eyes with multiple unacceptable fitting events will be counted only once. Fit rates of the Control lens will also be collected but are not a primary endpoint.
Number of Grade 3 or Higher Slit Lamp FindingsUp to 2-Week Follow-up EvlauationSlit Lamp Findings (SLF) were assessed using a biomicroscope and was graded using the FDA grading scale (Grade: 0, 1,2, 3 and 4) with grade 0 represents the absence of findings and 1 to 4 representing successively worse findings (i.e. Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe). Slit Lamp Findings will be assessed for each subject eye at all study visits (schedule and unscheduled). SLF is a binary response where Y=1 for at least one Grade 3 or 4 slit lamp finding. The percentage of eyes with Grade 3 or higher slit lamp findings will be analyzed and will include corneal infiltrates. Eyes with multiple events will be counted only once. The number of eyes with SLF with grade 3 or higher by lens was reported.
Overall Comfort Score2-Week Follow-up EvlauationOverall comfort was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patientexperience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.
Distance Visual Acuity2-Week Follow-up EvlauationDistance visual acuity was assessed by eye using LogMAR visual acuity at 4 meters using an ETDRS chart under high illumination high contrast conditions (room illumination \> 400 lux and chart luminance 120-200 cd/m2) at the 2-week follow-up for each subject eye. Lower values of logMAR indicate better vision, where a score of 0.0 equates to 20/20 snellen vision. The average visual acuity for each lens was reported.

Secondary

MeasureTime frameDescription
Overall Quality of Vision Score2-Week Follow-up EvlauationOverall quality of vision was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patientexperience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.
Overall Handling Score2-Week Follow-up EvlauationOverall handling was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patientexperience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.

Countries

United States

Participant flow

Recruitment details

A total of 253 subjects were enrolled into this study. Of those 2 subjects failed to meet all eligibility criteria and 251 subjects were dispensed a study lens. of the dispensed subjects 248 completed the study while 3 subjects were discontinued.

Participants by arm

ArmCount
Test
Subjects that wore the Test lens in both eyes during the entire duraiton of the study.
125
Control
All subjects dispensed the Control lens in both eyes throughout the entire duration of the study.
126
Total251

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyProtocol Violation01
Overall StudyUnsatisfactory Lens Fitting10
Overall StudyUnsatisfactory Visual Response10

Baseline characteristics

CharacteristicControlTotalTest
Age, Continuous31.7 Years
STANDARD_DEVIATION 6.73
31.1 Years
STANDARD_DEVIATION 6.67
30.5 Years
STANDARD_DEVIATION 6.59
Race/Ethnicity, Customized
Asian
11 Participants21 Participants10 Participants
Race/Ethnicity, Customized
Black or African American
4 Participants4 Participants0 Participants
Race/Ethnicity, Customized
Other
2 Participants2 Participants0 Participants
Race/Ethnicity, Customized
White
109 Participants224 Participants115 Participants
Region of Enrollment
United States
126 Participants251 Participants125 Participants
Sex: Female, Male
Female
84 Participants169 Participants85 Participants
Sex: Female, Male
Male
42 Participants82 Participants40 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 1250 / 126
other
Total, other adverse events
0 / 1250 / 126
serious
Total, serious adverse events
0 / 1250 / 126

Outcome results

Primary

Contact Lens Fitting Acceptance Rate

Acceptable lens fit will be assessed at all study visits (scheduled and unscheduled) for each subject eye. Fit acceptance rate will be based on the lens fit acceptance of eyes wearing the Test lens only. Fit acceptance is a binary response where Y=1 if lens fit is acceptable and Y=0 otherwise. Unacceptable is defined as unacceptable if any one of the following criteria: * limbal exposure at primary gaze or with extreme eye movement; * edge lift; * excessive movement in primary up gaze; * insufficient movement in all three of the following conditions: primary gaze, up gaze, and push up test. Eyes with multiple unacceptable fitting events will be counted only once. Fit rates of the Control lens will also be collected but are not a primary endpoint.

Time frame: Up to 2-Week Follow-up

Population: All subjects that were dispsensed a study lens.

ArmMeasureValue (NUMBER)
TestContact Lens Fitting Acceptance Rate99.2 Percentage of eyes
ControlContact Lens Fitting Acceptance Rate100 Percentage of eyes
Comparison: It was calculated that 100 participants were required to show that the acceptable lens fitting for the Test lens would be superior to 90% with at least 80% power. Sample size was determined using simulations methods for repeated measures.95% CI: [98.5, 100]Bayesian Beta-Binomial Model
Primary

Distance Visual Acuity

Distance visual acuity was assessed by eye using LogMAR visual acuity at 4 meters using an ETDRS chart under high illumination high contrast conditions (room illumination \> 400 lux and chart luminance 120-200 cd/m2) at the 2-week follow-up for each subject eye. Lower values of logMAR indicate better vision, where a score of 0.0 equates to 20/20 snellen vision. The average visual acuity for each lens was reported.

Time frame: 2-Week Follow-up Evlauation

Population: Subjects that completed all study visits without a major protocol deviation impacting a primary endpoint.

ArmMeasureValue (MEAN)Dispersion
TestDistance Visual Acuity-0.131 logMARStandard Deviation 0.0913
ControlDistance Visual Acuity-0.107 logMARStandard Deviation 0.0861
Comparison: It was calculated that 30 participants randomized in a 1:1 fashion between the two lens types would have at least 80% power to detect a 0.05 difference in LogMAR visual acuity at the 2-week follow-up. Sample size was determined using simulations methods for repeated measures.95% CI: [-0.04, -0.01]Bayesian Normal Random effects model
Primary

Number of Grade 3 or Higher Slit Lamp Findings

Slit Lamp Findings (SLF) were assessed using a biomicroscope and was graded using the FDA grading scale (Grade: 0, 1,2, 3 and 4) with grade 0 represents the absence of findings and 1 to 4 representing successively worse findings (i.e. Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe). Slit Lamp Findings will be assessed for each subject eye at all study visits (schedule and unscheduled). SLF is a binary response where Y=1 for at least one Grade 3 or 4 slit lamp finding. The percentage of eyes with Grade 3 or higher slit lamp findings will be analyzed and will include corneal infiltrates. Eyes with multiple events will be counted only once. The number of eyes with SLF with grade 3 or higher by lens was reported.

Time frame: Up to 2-Week Follow-up Evlauation

Population: All subjects that were dispensed a study lens.

ArmMeasureValue (NUMBER)
TestNumber of Grade 3 or Higher Slit Lamp Findings0 Number of eyes
ControlNumber of Grade 3 or Higher Slit Lamp Findings0 Number of eyes
Comparison: It was calculated that 224 participants randomized in a 1:1 fashion between the two lens types would have at least 80% power to detect 5% difference between the Test and Control lens with respect to the proportion of eyes with Grade 3 or higher slit lamp findings across all study visits. Sample size was determined using simulations methods. Sample size for this study was primarily driven by the slit lamp findings.95% CI: [-0.007, 0.008]Bayesian beta-binomial model
Primary

Overall Comfort Score

Overall comfort was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patientexperience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.

Time frame: 2-Week Follow-up Evlauation

Population: All subjects that completed the study without a major protocol deviation impacting a primary endpoint.

ArmMeasureValue (MEAN)Dispersion
TestOverall Comfort Score64.7 Units on a ScaleStandard Deviation 21.33
ControlOverall Comfort Score62.6 Units on a ScaleStandard Deviation 23.38
Comparison: It was calculated that 224 participants randomized in a 1:1 fashion between the two lens types would have at least 80% power to detect a 5 points difference in mean overall comfort at he 2-week follow-up. Sample size was determined using Stroup's Method (alpha=0.05).95% CI: [-2, 8.5]Bayesian normal random-effects
Primary

Vision Satisfaction in Bright Lighting

Vision satisfaction in bright light was assessed using the individual item I was satisfied with the quality of my vision in bright lighting from the CLUE™ questionnaire. This item used the response scale, 1: Strongly Disagree, 2: Disagree, 3: Neither Agree nor Disagree, 4: Agree and 5: Strongly Agree. CLUE is the Contact Lens User Experience™ questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patient-experience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120. The Proportion of responses in each category were reported for each lens type.

Time frame: 2-Week Follow-up Evaluation

Population: Subjects that completed all study visits without a major protocol deviation impacting a primary endpoint.

ArmMeasureGroupValue (NUMBER)
TestVision Satisfaction in Bright LightingStrongly Agree30.3 Percentage of subjects
TestVision Satisfaction in Bright LightingAgree59.0 Percentage of subjects
TestVision Satisfaction in Bright LightingNeither Agree nor Disagree6.6 Percentage of subjects
TestVision Satisfaction in Bright LightingDisagree4.1 Percentage of subjects
TestVision Satisfaction in Bright LightingStrongly Disagree0 Percentage of subjects
ControlVision Satisfaction in Bright LightingStrongly Disagree0.8 Percentage of subjects
ControlVision Satisfaction in Bright LightingStrongly Agree19.4 Percentage of subjects
ControlVision Satisfaction in Bright LightingDisagree8.1 Percentage of subjects
ControlVision Satisfaction in Bright LightingAgree58.1 Percentage of subjects
ControlVision Satisfaction in Bright LightingNeither Agree nor Disagree12.9 Percentage of subjects
Comparison: It was calculated that 40 participants randomized in a 1:1 fashion between the two lens types would have at least 80% power to detect a 10% difference in proportion of subjects that reported at higher rating (Strongly Agree and Agree) with the Test compared to the Control lens at the 2-week follow-up. Sample size was determined using simulation-based methods (alpha=0.05).95% CI: [0.02, 0.15]Bayesian random -effects model
Secondary

Overall Handling Score

Overall handling was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patientexperience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.

Time frame: 2-Week Follow-up Evlauation

Population: All subjects that completed the study without a major protocol deviation impacting a primary endpoint.

ArmMeasureValue (MEAN)Dispersion
TestOverall Handling Score70.9 Units on a ScaleStandard Deviation 17.24
ControlOverall Handling Score68.7 Units on a ScaleStandard Deviation 18.55
Comparison: Sample Size was based on primary endpoints only.95% CI: [-1.3, 6.3]Bayesian normal random-effects
Secondary

Overall Quality of Vision Score

Overall quality of vision was assessed using the Contact Lens User Experience™ (CLUE) questionnaire. CLUE is a validated patient-reported outcomes (PRO) questionnaire to assess patientexperience attributes of soft contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Derived CLUE scores using Item Response Theory (IRT) follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response with a range of 0-120.

Time frame: 2-Week Follow-up Evlauation

Population: All subjects that completed the study without a major protocol deviation impacting a primary endpoint.

ArmMeasureValue (MEAN)Dispersion
TestOverall Quality of Vision Score66.4 Units on a ScaleStandard Deviation 19.19
ControlOverall Quality of Vision Score60.9 Units on a ScaleStandard Deviation 22.33
Comparison: Sample Size was based on primary endpoints only.95% CI: [3.48, 12.54]Bayesian normal random-effects

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026